Abstract
The use of transition metal complexes as anti-cancer agents became most practiced since the discovery and approval of cis-platin in 1978. Different analogues of platinum complexes were discovered and further investigated to find maximum efficiency on the target. But it was soon realized, the Pt-complexes had numerous side effects like resistance, neurotoxicity, etc. by which they couldn't reach to their final expectation. Hence, scientists researched other efficient alternatives, which can defeat the limitations of platinum analogues and shows capability in induced tumour cell death. In this review, we attempted to discuss how rhodium analogues can be a better alternative than cis-platin as an anti-cancer agent.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
